• Home
• Market Capitalization Definitions
• Small Cap ETF List
• Small Cap Keywords

Subscribe

• Bulletin Board News
• Penny Stock News
• Pink Sheets News
• Small Cap News
• Stock News
• Uncategorized

Intellect Neurosciences Announces New Findings Supporting its Patented ANTISENILIN Platform Technology for the Treatment of Alzheimer’s Disease

...continued
brain neuroscience Drugs 

Related posts:

1. Intellect Neurosciences Receives Notice of Allowance from United States Patent and Trademark Office for its ANTISENILIN( Alzheimer’s Disease Immunotherapy Technology Platform
2. Intellect Neurosciences Receives Notice of Allowance from United States Patent and Trademark Office for its ANTISENILIN( Alzheimer’s Disease Immunotherapy Technology Platform
3. Intellect Neurosciences Files New Patent Applications for Immunotherapy Methods to Target Abnormal Tau Protein in Treatment of Alzheimer’s disease
4. Intellect Neurosciences and Medical Research Council Technology Announce Humanization of Next-Generation Monoclonal Antibody to Amyloid Beta With Reduced Potential for Inflammation in the Brain of Alzheimer’s Patients
5. Intellect Neurosciences Responds to Official Action by United States Patent and Trademark Office in Relation to its ANTISENILIN( Alzheimer’s Patent Application

IIROC Trade Resumption – Lorus Therapeutics Inc.

...continued
Healthcare Drugs 

Related posts:

1. IIROC Trade Halt – Lorus Therapeutics Inc.
2. BrainStorm Cell Therapeutics Issues CEO Update to Shareholders
3. Nile Therapeutics, Inc. to Raise $1.4 Million in Registered Direct Offering
4. BrainStorm Cell Therapeutics Expands Pipeline with the Initiation of a Study for Multiple Sclerosis
5. Cannabis Science Confirms Two Extract-Based Formulations Are Both Available Now at Cannabis Therapeutics and Marisol Therapeutics in Colorado

IIROC Trade Halt – Lorus Therapeutics Inc.

...continued
Healthcare Drugs 

Related posts:

1. Fannie, Freddie halt evictions for holiday
2. BrainStorm Cell Therapeutics Issues CEO Update to Shareholders
3. Nile Therapeutics, Inc. to Raise $1.4 Million in Registered Direct Offering
4. BrainStorm Cell Therapeutics Expands Pipeline with the Initiation of a Study for Multiple Sclerosis
5. Cannabis Science Confirms Two Extract-Based Formulations Are Both Available Now at Cannabis Therapeutics and Marisol Therapeutics in Colorado

LipiGesic(tm) M is Recognized by Headache Experts as an Excellent First-Line Therapy for Acute Migraine Treatment

...continued
mems shareholders shares ...continued
Healthcare Drugs 

Related posts:

1. Health Canada Approves CAMBIA(R) for the Treatment of Acute Migraine
2. PuraMed BioScience, Inc. Announces LipiGesic(M, Their Unique Migraine Treatment, is Now Available for Purchase at CVS, the 2nd Largest Drug Chain in the United States
3. PuraMed BioScience(, Inc. Reports Increased Revenue From Sales of LipiGesic( M, Its Flagship Migraine Pain Relief Product
4. Stellar to Hold Conference Call re Health Canada Approval of CAMBIA(R) for the Treatment of Acute Migraines
5. PuraMed BioScience , Inc., Launches a Marketing Blitz for LipiGesic M, Its Clinically-Tested Migraine Pain Reliever in the Denver, CO Region to Coincide with the NACDS’s Marketplace 2012 Trade Convention

Oramed Pharmaceuticals to Present at the 12th Annual Diabetes Technology Society Meeting in Bethesda, MD, Nov 8-10, 2012

...continued
pharmaceuticals pharma Drugs 

Related posts:

1. Oramed Pharmaceuticals Chosen to Present at the XVI International Symposium on Atherosclerosis (ISA2012), (March 25-29, 2012; Sydney, Australia)
2. Oramed Pharmaceuticals Granted Australian Patent for Important Part of the Company’s Core Technology in Oral Delivery of Proteins
3. International Stem Cell Corporation Scientists to Present Pre-Clinical Research Results at American Society of Gene and Cell Therapy 15th Annual Meeting
4. Unigene To Present at the 2012 Obesity Society’s 30th Annual Scientific Meeting
5. TONIX Pharmaceuticals to Present at the 14th Annual Bio CEO & Investor Conference on February 14, 2012

Advantages of Pressure BioSciences’ PCT Platform Highlighted at a Recent International Scientific Conference Focused on the Role of Proteins in the Cause, Prevention, and Treatment of Disease

...continued
Dental dna Drugs 

Related posts:

1. Pressure BioSciences Common Stock to Begin Trading Today on the OTCQB(TM) Tier of the OTC Marketplace
2. Reprints Desk to Present on Management of Bibliographic and Scientific Information at Pharma-Bio-Med & BioSciences Conference
3. Intellect Neurosciences Files New Patent Applications for Immunotherapy Methods to Target Abnormal Tau Protein in Treatment of Alzheimer’s disease
4. Intellect Neurosciences Receives Notice of Allowance from United States Patent and Trademark Office for its ANTISENILIN( Alzheimer’s Disease Immunotherapy Technology Platform
5. Amarantus BioSciences Licenses Parkinson’s Disease Diagnostic Biomarker Test from Power3 Medical Products

Shengtai Pharmaceutical, Inc. Reports Financial Results for the Fiscal Year 2012

...continued
Healthcare Drugs 

Related posts:

1. Shengtai Pharmaceutical, Inc. Reports Second Quarter Fiscal Year 2012 Financial Results
2. China New Media Reports First Quarter Fiscal Year 2012 Financial Results
3. China New Media Reports Second Quarter Fiscal Year 2012 Financial Results
4. LianDi Clean Technology Inc. Reports Financial Results for Second Quarter of Fiscal Year 2012
5. Shengtai Pharmaceutical Inc. Announces Results of the 2011 Annual Shareholders Meeting

Champions Oncology Notes Front Page Article Discussing Personalized TumorGraft In The New York Times

...continued
Drugs Healthcare 

Related posts:

1. Champions Oncology Reports Financial Results for the Quarter Ended July 31, 2012
2. Champions Oncology Reports Fiscal 2012 Third Quarter Financial Results
3. North American Nickel Featured on the Front Page of the Northern Miner
4. Champions Oncology CEO to Speak at Harris and Harris Group’s "Meet the Portfolio" Day
5. Champions Oncology, Inc. Appoints Executive Vice President and Chief Financial Officer to Management Team and Corporate Office Relocation

Emisphere Technologies, Inc. Announces Default on Approximately $31.1 Million Notes Due to MHR Fund Management LLC and Its Affiliated Funds; MHR Has Not Demanded Payment; The Company and MHR Continue Discussions

...continued
Drugs biotechnology pharmaceuticals 

Related posts:

1. Payment Data Systems Announces November Transactions Continue the Trend for Extraordinary Growth in Transactions Processed
2. Markray Announces That the Company is Engaged in Buyout Discussions
3. Salamon Issues $5 Million Convertible Secured Notes to Radiant Funds and Haverstock Fund
4. Salamon Issues $5 Million Convertible Secured Notes to Radiant Funds and Haverstock Fund
5. Payment Data Systems Announces "Debit Only" Payment Product Offering

Momentum Hunter Morning Report: Pristine Solutions, Save the World Air, Applied DNA Sciences, Cellceutix Corp.

...continued
Drugs adams emissions 

Related posts:

1. Research Report on Pristine Solutions, Inc. and Chimera Energy Corp — Weighing the Weeks Ahead
2. CBS NY – Applied DNA Sciences Digital DNA May Soon Be Required To Take SAT And ACT Exams
3. CBS NY – Applied DNA Sciences Digital DNA May Soon Be Required To Take SAT And ACT Exams
4. OTC Stock Review Issues Report on Anavex Life Sciences Corp.
5. Club Penny Stocks Volume Focus List: Stevia First Corp. Pristine Solutions Inc …

Unigene To Present at the 2012 Obesity Society’s 30th Annual Scientific Meeting

...continued
...continued
...continued
pharmaceuticals Drugs investment 

Related posts:

1. Unigene to Present at the 14th Annual BIO CEO & Investor Conference on February 13, 2012
2. InVivo Therapeutics Announces Webcast for Annual Shareholders Meeting to Be Held on May 30th
3. Nile Therapeutics Announces Upcoming Data Presentation at the American College of Cardiology Annual Scientific Meeting
4. Novelos Therapeutics and Academic Collaborators Present Three Posters at 2012 AACR Annual Meeting
5. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012

Adherex Comments on Remedial Delisting Review Initiated by the Toronto Stock Exchange

...continued
Drugs Healthcare 

Related posts:

1. Adherex Comments on Remedial Delisting Review Initiated by the Toronto Stock Exchange
2. Northcore Comments on Delisting Review Initiated by Toronto Stock Exchange
3. Northcore Comments on Status of Delisting Review Initiated by Toronto Stock Exchange
4. PNI Digital Media Shares to Trade on Toronto Stock Exchange
5. Energizer Resources to Exhibit & Present at the 2012 PDAC International Trade Show & Investors Exchange, Toronto Ontario-Booth 2348

Adherex Comments on Remedial Delisting Review Initiated by the Toronto Stock Exchange

...continued
Drugs Healthcare ...continued
Drugs Healthcare 

Related posts:

1. Northcore Comments on Delisting Review Initiated by Toronto Stock Exchange
2. Northcore Comments on Status of Delisting Review Initiated by Toronto Stock Exchange
3. PNI Digital Media Shares to Trade on Toronto Stock Exchange
4. Energizer Resources to Exhibit & Present at the 2012 PDAC International Trade Show & Investors Exchange, Toronto Ontario-Booth 2348
5. American Oriental Bioengineering Inc. Announces Suspension of Trading in its Common Stock and the Initiation of Delisting Proceedings by NYSE

Champions Oncology Reports Financial Results for the Quarter Ended July 31, 2012

...continued
Healthcare Drugs 

Related posts:

1. Champions Oncology Reports Fiscal 2012 Third Quarter Financial Results
2. Trimedyne Reports Its Financial Results for the Quarter and Nine Months Ended June 30, 2012
3. SPY Inc. Reports Financial Results for the Quarter Ended June 30, 2012
4. Cornerstone Community Bank Reports Financial Results for the First Quarter Ended March 31, 2012
5. Nile Therapeutics Reports 2012 First Quarter Financial Results

LifeVantage Corporation Receives Approval to List on the NASDAQ Capital Market

...continued
barrier Drugs critical 

Related posts:

1. Attunity Files Application for Relisting on the NASDAQ Capital Market and Announces Special Meeting of Shareholders
2. Lithium Corporation Receives San Emidio Drill Permit Approval
3. LifeVantage Corporation Expands Management Team to Further Strategic Corporate Objectives
4. UTHealth Receives FDA Approval To Market New Coronary Flow Reserve Quantification Software
5. Pharmaxis Receives Approval to Market Bronchitol in the EU

Quick-Med Technologies Announces Further Expansion of Its NIMBUS(R) Technology Global Patent Portfolio

...continued
antimicrobial Healthcare Drugs 

Related posts:

1. USPTO Grants Quick-Med Technologies Sixth NIMBUS(R) Patent
2. Quick-Med Expands NIMBUS(R) Technology Into Advanced Wound Care Dressings
3. New Energy Strengthens Patent Portfolio in Effort to Commercialize First-of-their-Kind Technologies for Generating Clean Electricity
4. Generex Announces Patent Award for its Core Vaccine Technologies in Japan
5. Quick-Med Technologies to Present Stay Fresh(R) Antimicrobial at AATCC International Conference

UPCOMING DEADLINE: Levi & Korsinsky Notifies Investors With Losses on Their Investment in PolyMedix, Inc. of Class Action Lawsuit and the Deadline of August 31, 2012 to Seek a Lead Plaintiff Position — PYMX

...continued
heparin Drugs mrsa 

Related posts:

1. UPCOMING DEADLINE: Levi & Korsinsky Notifies Investors With Losses on Their Investment in General Maritime Corporation of Class Action Lawsuit and the Deadline of August 27, 2012 to Seek a Lead Plaintiff Position
2. Deadline Tomorrow: The Law Firm of Levi & Korsinsky Notifies Investors with Losses on Their Investment in China Sky One Medical, Inc. of Class Action Lawsuit and the Deadline of April 24, 2012 to Seek a Lead Plaintiff Position
3. The Law Firm of Levi & Korsinsky Notifies Investors with Losses on Their Investment in Olympus Corporation of Class Action Lawsuit and the Deadline of January 13, 2012 to Seek a Lead Plaintiff Position
4. Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in General Maritime Corporation to Inquire About the Lead Plaintiff Position in Securities Fraud Class Action Lawsuit
5. The Rosen Law Firm Reminds Investors of Important August 31, 2012 Deadline in Securities Class Action Against PolyMedix, Inc. — PYMX

Nile Therapeutics Reports 2012 Second Quarter Financial Results

...continued
Drugs Healthcare 

Related posts:

1. Nile Therapeutics Reports 2012 First Quarter Financial Results
2. Nile Therapeutics Reports 2011 Third Quarter Financial Results
3. Talon Therapeutics, Inc. Reports First Quarter 2012 Financial Results
4. InVivo Therapeutics Reports First Quarter 2012 Financial Results, Provides Business Update
5. Pivotal Therapeutics Reports 1st Quarter 2012 Results

Unleash the Urge to Splurge- Why Luxury Holidays are Becoming so Popular

...continued
Drugs Healthcare ...continued

Related posts:

1. Omni Announces Luxury Market Strategy: "INVASION OF PRVCY" as Multi Billion Dollar Luxury Brands Continue to Out Perform Other Retail Sectors
2. Radical Entertainment( and Dark Horse Join Forces to Unleash the Ultimate Shape-Shifting Comic Series
3. Epson Offers Twelve Incredible Deals for the Holidays
4. Luxury and Excitement Hit the Spanish Market at iPoker’s iPOPS Live Barcelona
5. In Respect of Holidays Herborium Group Planned Announcement Moved to the Following Week

CanCHEW Bio-Technologies, a Medical Marijuana Inc. Product, Dr. George Anastassov Appeared on Small Cap Voice Internet Radio Program To Discuss The CanCHEW Advantage

...continued
intro music Drugs ...continued

Related posts:

1. CEO Angel Stanz of BG Medical Technologies Talks to "The Stock Radio" About the Medical Marijuana Industry, Natural Medicine Technology, and 2012 Goals
2. Medical Marijuana, Inc. Acquires 50% Stake in CanChew from Netherlands-based Sanammad Foundation
3. BG Medical Technologies Leads the Medical Marijuana Industry in Providing Transparency to Investors
4. Medical Marijuana Business Daily Article Highlights Medical Marijuana, Inc. Line of Hemp-Based, THC-Free Products and the Growing Promise of Cannabidiol
5. Marijuana, Inc.’s Division MarijuanaInc.TV Captures the Spirit of the Medical Marijuana Movement on 4/20/2012

Nile Therapeutics Promotes Darlene Horton, M.D., to Chief Executive Officer and Director

...continued
simulators Services training ...continued
...continued
Healthcare Drugs 

No related posts.

Bond Labs to Unveil Innovative New Products at the GNC Global Franchise Convention

Bond Laboratories, Inc. (OTCBB:BNLB) today announced that its wholly owned operating division, NDS Nutrition Products (“NDS”) http://ndsnutrition.com, will be launching several exciting new products at the annual GNC ® Global Franchise Convention June 24-26 th in Washington, D.C., during which NDS will showcase its current top selling products and introduce its latest product innovations -- Nitro CMX ® , Pump Fuel v. 2 ® , and Pump Fuel Insanity ® . NDS is a nation...continued
BNLB  Drugs Healthcare 

Related posts:

1. Bond Labs Launches Innovative New Product Stack
2. Bond Labs Strengthens its Credit Facility
3. Bond Labs Achieves Turnaround; Generating Record 2011 Results
4. Product Innovation Drives Record Results for Bond Laboratories
5. NuVitality Labs enters $60 billion weight loss market with 3 new products

Nile Therapeutics Appoints Darlene Horton, M.D., as Chief Medical Officer

SAN MATEO, Calif., June 21, 2012 /PRNewswire/ -- Nile Therapeutics, Inc. (OTCQB: NLTX), a biopharmaceutical company that develops novel therapeutics for heart failure patients, today announced that it appointed Darlene Horton, M.D. as its Chief Medical Officer. Dr. Horton was previously Chief Medical Officer of Itero Biopharmaceuticals, a venture-backed company that developed and out-licensed a biosimilar protein therapeutic. Previous to Itero, Dr. Horton served as Senior Vice President, Clinical R...continued
NLTX  Healthcare Drugs 

Related posts:

1. Nile Therapeutics, Inc. Completes $1.34 Million Registered Direct Offering
2. Nile Therapeutics Announces Positive Clinical Trial Results Evaluating the Subcutaneous Infusion of Cenderitide
3. Nile Therapeutics Announces Upcoming Data Presentation at the American College of Cardiology Annual Scientific Meeting
4. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
5. Nile Therapeutics, Inc. to Raise $1.4 Million in Registered Direct Offering

Stellar Pharmaceuticals Acquires the Exclusive Rights to Collatamp G(R) in Canada

- Stellar strengthens its Specialty Care Products business with Collatamp G(R) (gentamicin impregnated sponge) acquisition MILTON, ONTARIO--(Marketwire - June 20, 2012) - Stellar Pharmaceuticals Inc. ("Stellar") (OTCQB:SLXCF)(OTCBB:SLXCF)(PINKSHEETS:SLXCF) today announced that it has acquired the Canadian rights for Collatamp G ® from Theramed Corporation. Collatamp G® is approved in over 50 countries for the local haemostasis of capillary, parenchymatous and seeping haemorrhages in are...continued
SLXCF  Healthcare neovisc Drugs 

Related posts:

1. Apricus Biosciences and Stellar Pharmaceuticals Announce Exclusive License Agreement in Canada for the Commercialization of MycoVa(TM) for Onychomycosis
2. Stellar to Acquire Tribute Pharmaceuticals to Create Premier North American Specialty Pharmaceutical Company
3. Stellar Pharmaceuticals Inc.: Conference Call
4. Stellar Pharmaceuticals to Present at the Bloom Burton Investor Conference June 21
5. Stellar Pharmaceuticals Strong Product Sales in 2011; Builds for the Future

Advaxis to Present at the 2012 BIO International Convention

Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that Thomas Moore, Chairman & CEO of Advaxis, will present at the 2012 BIO International Convention. Hosted by the Biotechnology Industry Organization (BIO), this year’s global event for biotechnology will take place June 18-21, 2012 at the Boston Convention and Exhibition Center in Boston, MA. About the BIO International Convention The BIO In...continued
ADXS  listeria Healthcare Drugs 

Related posts:

1. Advaxis to Present at the 6th Annual International BIO-Europe Spring 2012 Conference
2. Advaxis to Present at the Inaugural Marcum MicroCap Conference on June 20th in NYC
3. Advaxis to Present at the 14th Annual BIO CEO & Investor Conference
4. Advanced Cell Technology to Present at the 2012 Bio International Convention and the Clinical Outlooks for Regenerative Medicine Meeting
5. TRX to Present at the 2012 GBTA International Convention & Exposition

Next Page »

Tags

About anyone bank Banking banks Best Drugs Energy Financial find FREE from gold good Healthcare Inc. invest investing investment Latest List market mining money mortgage news Newsletter Online Penny pick Picks Review Services shares some stock stocks Technology this Tips trade trading video Volume Watch

Latest from Twitter

• No public Twitter messages.

Categories

• Bulletin Board News
• Penny Stock News
• Pink Sheets News
• Small Cap News
• Stock News
• Uncategorized

Archives

• May 2013
• April 2013
• March 2013
• February 2013
• January 2013
• December 2012
• November 2012
• October 2012
• September 2012
• August 2012
• July 2012
• June 2012
• May 2012
• April 2012
• March 2012
• February 2012
• January 2012
• December 2011
• November 2011
• October 2011

Copyright © 2013 Small Cap Updates